98%
921
2 minutes
20
Kidney complications have been studied in allogeneic hematopoietic stem cell transplant patients but not specifically among chronic graft-versus-host disease (cGVHD) patients. Participants (n = 365) enrolled in the cross-sectional cGVHD natural history study (NCT00092235) were assessed for kidney dysfunction and overall survival. Kidney dysfunction was analyzed for associations in univariate and multivariable analyses. Kidney dysfunction (eGFR < 60) was found in 64 patients, and 29 patients had moderate-severe kidney dysfunction (eGFR < 45). Patients with kidney dysfunction were more likely treated with cyclosporine at evaluation or to have received it for GVHD prophylaxis, or prior treatment of GVHD. Patients with kidney dysfunction were less severely affected by cGVHD of skin, mouth, and joints/fascia. In multivariable modeling, history of cyclosporine use (OR = 2.19, 95% CI 1.13-4.25), angiotensin receptor blocker use (OR = 5.57, 95% CI 1.49-20.84), proteinuria (OR = 2.39, 95% CI 1.19-4.79), lower CRP (OR = 0.95, 95% CI 0.91-0.99), lower C3 (OR = 0.98, 95% CI 0.97-0.99), and lower hemoglobin (OR = 0.70, 95% CI 0.58-0.84) were jointly associated with kidney dysfunction. Overall survival was lower in those with moderate-severe kidney dysfunction (p = 0.015), demonstrating the importance of addressing kidney dysfunction in this population. The association of kidney dysfunction with less severe cGVHD suggests an etiology unrelated to cGVHD but potentially a consequence of drug-related toxicities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983272 | PMC |
http://dx.doi.org/10.1038/s41409-023-02032-1 | DOI Listing |
Gen Physiol Biophys
September 2025
The Second Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Diabetic nephropathy (DN) is a major complication of diabetes, imposing substantial socioeconomic and public health challenges. N6-methyladenosine (m6A) modification, a prevalent epigenetic mechanism, influences cellular processes and disease progression. Wilms' tumor 1-associating protein (WTAP), an m6A methyltransferase subunit, was investigated for its role in DN.
View Article and Find Full Text PDFG Ital Nefrol
August 2025
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
The prevalence of obesity is progressively increasing on a global scale. Among its negative health consequences, renal damage is also observed. It is due to hemodynamic, metabolic, and inflammatory alterations.
View Article and Find Full Text PDFCureus
August 2025
Internal Medicine, St Luke's Hospital, Easton, USA.
Streptococcal toxic shock syndrome (STSS) is a rare but life-threatening illness characterized by rapid progression to multi-organ failure. This is a case of a middle-aged male patient who initially presented with localized chest wall pain, erythema, vomiting, and diarrhea. These nonspecific symptoms rapidly progressed to systemic shock and multi-organ dysfunction, including acute kidney injury, pleural effusions, demand ischemia of the heart, and the development of a characteristic diffuse, sunburn-like rash.
View Article and Find Full Text PDFCureus
August 2025
Gastroenterology and Hepatology, Nassau University Medical Center, East Meadow, USA.
This case report presents a complex case of acute cholecystitis, cholangitis, pancreatitis, intrahepatic abscesses, and sepsis without biliary obstruction, highlighting the challenges of managing multi-organ involvement in a critically ill individual. The patient, a middle-aged male, presented with fever, jaundice, and abdominal pain, with imaging revealing biliary ductal dilation, a distended gallbladder, and a staghorn calculus. Laboratory findings showed elevated liver enzymes, bilirubin, and lipase, supporting the diagnosis of acute cholecystitis, cholangitis, and pancreatitis.
View Article and Find Full Text PDFCureus
August 2025
Department of Cardiology, Apollo Hospitals, Indore, IND.
The cardiovascular continuum is the developmental process of cardiovascular diseases (CVDs) leading to heart failure (HF) and sudden cardiac death. Beta-blockers (BBs) are at the forefront of managing conditions along this continuum, ranging from cardiovascular (CV) risk factors to heart failure. In particular, bisoprolol proved to be a highly cardio-selective BB with a favourable pharmacokinetic profile, demonstrating long-term safety, good tolerability, and proven efficacy in reducing cardiac events, including arrhythmias and mortality in patients with heart failure with reduced ejection fraction (HFrEF).
View Article and Find Full Text PDF